Amaia Lujambio Goizueta

Search results

• New Findings from Icahn School of Medicine at Mount Sinai Update Understanding of Liver Cancer (Wntinib Is a Multi-kinase Inhibitor With Specificity Against B-catenin Mutant Hepatocellular Carcinoma)

  Schwarz, M., Torre, D., Lujambio, A., Khan, Z., Llovet, J., Jin, J., Guccione, E., Villanueva Rodriguez, A., Dar, A. & Lujambio Goizueta, A.

  21/02/24

  1 item of Media coverage

  Press/Media

• Icahn School of Medicine at Mount Sinai Researcher Releases New Data on Cancer Gene Therapy (The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma)

  Lujambio, A. & Lujambio Goizueta, A.

  14/02/24

  1 item of Media coverage

  Press/Media

• Study Results from Icahn School of Medicine at Mount Sinai in the Area of Liver Cancer Reported (Wntinib Is a Multi-kinase Inhibitor With Specificity Against & Beta;-catenin Mutant Hepatocellular Carcinoma)

  Schwarz, M., Torre, D., Lujambio, A., Llovet, J., Jin, J., Guccione, E., Villanueva Rodriguez, A., Dar, A., Lujambio Goizueta, A. & Khan, Z.

  6/09/23

  1 item of Media coverage

  Press/Media

• Reports from Icahn School of Medicine at Mount Sinai Highlight Recent Findings in Glioblastomas (Monocyte Depletion Enhances Neutrophil Influx and Proneural To Mesenchymal Transition In Glioblastoma)

  Lindblad, K., Lujambio, A., Tsankov, A., Lira, S., Tsankova, N., Lujambio Goizueta, A., Chen, Z. & Giotti, B.

  24/07/23

  1 item of Media coverage

  Press/Media

• Spanish researchers develop new immunotherapy combination for liver cancer

  Lujambio, A. & Lujambio Goizueta, A.

  1/07/23

  1 item of Media coverage

  Press/Media

• Nanoparticles Designed to Multiply the Efficacy of Immunotherapy

  Lujambio, A. & Lujambio Goizueta, A.

  5/10/22

  1 item of Media coverage

  Press/Media

• Follow the Money: Cloud R&D, Generative Biology, Robotics

  Lujambio, A., Guccione, E., Lujambio Goizueta, A. & Dar, A.

  2/12/21

  3 items of Media coverage

  Press/Media

• Mount Sinai Researchers Awarded $3.15 Million to Advance a Multidisciplinary Drug Development Platform for Hepatocellular Carcinoma

  Lujambio, A., Schwartz, M., Guccione, E., Lujambio Goizueta, A. & Dar, A.

  30/11/21 → 1/12/21

  2 items of Media coverage

  Press/Media

• Mount Sinai Researchers Awarded $3.15 Million to Advance a Multidisciplinary Drug Development Platform for Hepatocellular Carcinoma.

  Lujambio, A., Schwartz, M., Guccione, E., Lujambio Goizueta, A. & Dar, A.

  30/11/21

  1 item of Media coverage

  Press/Media

• Mount Sinai Researchers Awarded $3.15 Million to Advance a Multidisciplinary Drug Development Platform for Hepatocellular Carcinoma; The National Cancer Institute has awarded Mount Sinai researchers $3.15 million in grant funding to assess the potential o

  Lujambio, A., Schwartz, M., Guccione, E., Lujambio Goizueta, A. & Dar, A.

  30/11/21

  18 items of Media coverage

  Press/Media

• Studying the Tumor Microenvironment of Hepatocellular Carcinoma

  Lujambio, A. & Lujambio Goizueta, A.

  8/09/21

  1 item of Media coverage

  Press/Media

• Understanding the Molecular Diverse Makeup of Hepatocellular Carcinom

  Lujambio, A. & Lujambio Goizueta, A.

  4/09/21

  1 item of Media coverage

  Press/Media

• 15th Annual Meeting Set for Sept. 3 by International Laser Class Association

  Lujambio, A. & Lujambio Goizueta, A.

  30/07/21

  1 item of Media coverage

  Press/Media

• 15th Annual Meeting Set for Sept. 2 by International Laser Class Association

  Lujambio, A. & Lujambio Goizueta, A.

  30/07/21

  1 item of Media coverage

  Press/Media

• Liver Cancer Tumors Appear to Be Resistant to Immunotherapy

  Lujambio, A., Marron, T., Lujambio Goizueta, A. & Llovet, J.

  25/03/21

  1 item of Media coverage

  Press/Media

• Mount Sinai Hospital: Liver Cancer Tumors Appear to Be Resistant to Immunotherapy in Patients With Underlying Non-Alcoholic Steatohepatitis

  Lujambio, A., Marron, T., Lujambio Goizueta, A. & Llovet, J.

  25/03/21

  1 item of Media coverage

  Press/Media

• Liver Cancer Tumors Appear to Be Resistant to Immunotherapy in Patients With Underlying Non-alcoholic Steatohepatitis (NASH).

  Lujambio, A., Marron, T., Lujambio Goizueta, A. & Llovet, J.

  24/03/21

  1 item of Media coverage

  Press/Media

• Liver Cancer Tumors Appear to Be Resistant to Immunotherapy in...

  Lujambio, A., Marron, T., Lujambio Goizueta, A. & Llovet, J.

  24/03/21

  1 item of Media coverage

  Press/Media

• Mount Sinai: Liver Cancer Tumors Appear to Be Resistant to Immunotherapy in Patients With Underlying Non-alcoholic Steatohepatitis (NASH)

  Lujambio, A., Marron, T., Lujambio Goizueta, A. & Llovet, J.

  24/03/21

  1 item of Media coverage

  Press/Media

• Liver Cancer Tumors Appear to Be Resistant to Immunotherapy in...

  Lujambio, A., Marron, T., Lujambio Goizueta, A. & Llovet, J.

  24/03/21

  13 items of Media coverage

  Press/Media

• Liver Cancer Tumors Appear to Be Resistant to Immunotherapy in Patients With Underlying Non-alcoholic Steatohepatitis (NASH)

  Lujambio, A., Marron, T., Lujambio Goizueta, A. & Llovet, J.

  24/03/21

  1 item of Media coverage

  Press/Media

• U.S. Patents Awarded to Inventors in Tennessee (Aug. 24)

  Lujambio, A. & Lujambio Goizueta, A.

  24/08/19

  1 item of Media coverage

  Press/Media

• St. Jude Children's Research Hospital, Emorial Sloan-Kettering Cancer Center Assigned Patent for Method, Kits for Identifying of CDK9 Inhibitors

  Lujambio, A. & Lujambio Goizueta, A.

  24/08/19

  1 item of Media coverage

  Press/Media

• Novel precision mouse models of liver cancer

  Lujambio, A. & Lujambio Goizueta, A.

  12/07/19

  1 item of Media coverage

  Press/Media

• NYU Abu Dhabi researchers unlock the secrets of liver regeneration

  Lujambio, A., Bernstein, E., Lujambio Goizueta, A., Sadler Edepli, K. & Wang, S.

  22/06/19

  1 item of Media coverage

  Press/Media